Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

New Developments Warrant Rethinking HCC Transplant Criteria

By Jared Kaltwasser

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock

Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

By Mary Caffrey

April 29th 2025

senior scientist | Image credit: Ohio State University

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

By Mary Caffrey

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

August 7th 2018

Liquid Biopsy Identifies Patients More Likely to Benefit From Immunotherapy in NSCLC

Samantha DiGrande

A blood-based test to assess tumor mutational burden (TMB) was recently discovered as being able to accurately identify patients with non–small cell lung cancer (NSCLC) who could benefit from checkpoint inhibitor treatment. The study, conducted by researchers at UC Davis, Genentech, and Foundation Medicine, was published in Nature Medicine.

August 4th 2018

FDA Accepts First Allogeneic CAR T-Cell Therapy Trial

Samantha DiGrande

Celyad, a biopharmaceutical company that focuses on the development of chimeric antigen receptor (CAR) T-cell therapies, recently announced that the FDA has accepted its Investigational New Drug (IND) application for CYAD-101, the first non–gene-edited allogeneic clinical program.

August 3rd 2018

AYAs With Blood Cancers Face Unique Psychosocial Issues That Impact Quality of Life

Laura Joszt, MA

In addition to survival among adolescents and young adults (AYAs) with hematological malignancies lagging behind that of children and older adults, AYAs also face unique challenges related to their physical, psychosocial, and economic circumstances.

August 3rd 2018

AJMC® in the Press, August 3, 2018

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

August 2nd 2018

Opdivo Approved for Adjuvant Treatment of Melanoma in European Union

Samantha DiGrande

Bristol-Myers Squibb recently announced that the European Commission has approved nivolumab (Opdivo) for the adjuvant treatment of adult patients with melanoma that have lymph node involvement or metastatic disease and who have undergone complete resection.

August 2nd 2018

Dana-Farber, Philips Partner to Expand Clinical Pathways Tool

Samantha DiGrande

The Dana-Farber Cancer Institute recently announced that it is partnering with Royal Philips in order to establish and provide improved clinical pathways in cancer care.

August 1st 2018

Advancing Precision Oncology With the Syapse Precision Medicine Council

In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council.

July 31st 2018

Cancer Screening Rates in the US Fall Short of Healthy People 2020 Targets

Jaime Rosenberg

Screening rates for cervical, breast, colorectal, and prostate cancers in the United States fall short of Healthy People 2020 targets and significant disparities exist among subgroups.

July 31st 2018

Oncology Care Model Not Immune to the Need for Intervention

Rita E. Numerof, PhD

With the evaluation period for the Oncology Care Model at its midway point, there is an opportunity to discuss how the program and other bundled payment programs can better deliver on aims to provide higher quality care at the same or lower cost.

July 28th 2018

Podcast: This Week in Managed Care—CMS to Resume Risk Adjustment Payments and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

July 27th 2018

This Week in Managed Care: July 27, 2018

This week, the top managed care stories included CMS reversing its decision to suspend the risk adjustment payment program; out-of-pocket costs and copayment accumulators put an HIV prevention drug out of reach for patients; research finds geography can determine posttreatment imaging for women with breast cancer.

July 27th 2018

Cytokine "Backpacks" for T Cells Increase Immune Response in Solid Tumors

Samantha DiGrande

A new study published in Nature Biotechnology found that by attaching a kind of cytokine “backpack” to T-cells through the use of a nanoparticle gel enhanced their efficacy in treating tumors in mice.

July 27th 2018

Oncology, CVD, Infectious Disease Most Common Areas for Outcomes-Based Contracts, Avalere Finds

Laura Joszt, MA

Health plans continue to show interest in expanding outcomes-based contracts, according to an Avalere Health study that also found cardiovascular diseases, infectious diseases, and oncology represent the most common therapeutic areas to have these contracts.

July 26th 2018

Exclusive Coverage of the 2018 American Society of Clinical Oncology Annual Meeting

July 26th 2018

CAR T-Cell Therapy Update

CAR T-Cell therapy updates presented at the American Society of Clinical Oncology's Annual Meeting held June 2018.

July 26th 2018

AJMCtv® Interviews, July 2018

Samantha DiGrande Jaime Rosenberg

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

July 26th 2018

Clinical Updates, July 2018

Samantha DiGrande

July 26th 2018

Prevention and Managed Care Updates

Jaime Rosenberg Mary Caffrey Kelly Davio Christine Potkul

July 26th 2018

Care Strategies

Surabhi Dangi-Garimella, PhD Jaime Rosenberg

Care strategies updates from the American Society of Clinical Oncology's Annual Meeting, held June 2018.

July 25th 2018

Addressing Unmet Needs in Multiple Myeloma

July 25th 2018

Second Myeloma Relapse and Beyond: Upcoming Strategies

July 25th 2018

Selecting Treatment at First Relapse of Multiple Myeloma

July 25th 2018

Optimizing Maintenance Therapy in Multiple Myeloma

July 25th 2018

Frontline Therapy's Impact on Later Treatment in MM

July 25th 2018

Multiple Myeloma: Frontline Daratumumab Combinations

July 25th 2018

Frontline Therapy Options for Multiple Myeloma

July 25th 2018

Approaching Upfront Treatment for Multiple Myeloma

July 25th 2018

Advent of Combination Strategies in Multiple Myeloma

July 25th 2018

Treating Multiple Myeloma at Second Relapse and Beyond

July 25th 2018

Treating Multiple Myeloma at First Relapse

...

39 40 41 42 43 44 45 46 47

...

184 >